GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced BioMedical Technologies Inc (OTCPK:ABMT) » Definitions » Net-Net Working Capital

Advanced BioMedical Technologies (Advanced BioMedical Technologies) Net-Net Working Capital : $-0.12 (As of Jul. 2021)


View and export this data going back to 2007. Start your Free Trial

What is Advanced BioMedical Technologies Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Advanced BioMedical Technologies's Net-Net Working Capital for the quarter that ended in Jul. 2021 was $-0.12.

The industry rank for Advanced BioMedical Technologies's Net-Net Working Capital or its related term are showing as below:

ABMT's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.58
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Advanced BioMedical Technologies Net-Net Working Capital Historical Data

The historical data trend for Advanced BioMedical Technologies's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced BioMedical Technologies Net-Net Working Capital Chart

Advanced BioMedical Technologies Annual Data
Trend Oct11 Oct12 Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.07 -0.08 -0.10 -0.11

Advanced BioMedical Technologies Quarterly Data
Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.11 -0.12 -0.12 -0.12

Competitive Comparison of Advanced BioMedical Technologies's Net-Net Working Capital

For the Medical Devices subindustry, Advanced BioMedical Technologies's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced BioMedical Technologies's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced BioMedical Technologies's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Advanced BioMedical Technologies's Price-to-Net-Net-Working-Capital falls into.



Advanced BioMedical Technologies Net-Net Working Capital Calculation

Advanced BioMedical Technologies's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Oct. 2020 is calculated as

Net-Net Working Capital(A: Oct. 2020 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.202+0.75 * 0+0.5 * 0.1-7.871
-0-0)/70.2249
=-0.11

Advanced BioMedical Technologies's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jul. 2021 is calculated as

Net-Net Working Capital(Q: Jul. 2021 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.007+0.75 * 0+0.5 * 0.189-8.579
-0-0)/70.2249
=-0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Advanced BioMedical Technologies  (OTCPK:ABMT) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Advanced BioMedical Technologies Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Advanced BioMedical Technologies's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced BioMedical Technologies (Advanced BioMedical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
200 Park Avenue, Suite 1700, New York, NY, USA, 10166
Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.
Executives
Advanced Biomedical Technologies Inc. director, officer: CFO 200 PARK AVENUE, SUITE 1700 NEW YORK NY 10166
Lynch John Thomas Jr other: Advisor 22 MULBERRY STREET SUITE 1B MIDDLETOWN NY 10940
Chi Ming Yu director, 10 percent owner, officer: PRESIDENT 36 CLAREMONT TERRACE WAYNE NJ 07470
Andriy Protskiv director, 10 percent owner, officer: President, CEO, CFO 706-15038 101 AVENUE SURREY A1 V3R 0N2

Advanced BioMedical Technologies (Advanced BioMedical Technologies) Headlines